Outcome of Board Meeting
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2015, inter alia, has take on record the following:1. Dr. M. U. R. Naidu appointed as Additional Director of the Company.2. Dr. D. Linga Rao, President (Technical Affairs) appointed as Additional Director of the Company who will be in the wholetime employment of the Company and be designated as Director & President (Technical Affairs).... Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2014
Natco Pharma Ltd has announced the following results for the quarter ended December 31, 2014:The Unaudited Standalone results for the Quarter ended December 31, 2014The Company has posted a net profit of Rs. 166.10 million for the quarter ended December 31, 2014 as compared to Rs. 324.20 million for the quarter ended December 31, 2013. Total Income has decreased from Rs. 1752.80 million for the quarter ended December 31, 2013 to Rs.... Board declares Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2015, inter alia, has recommended payment of an interim dividend of Rs. 5/- per equity share of Rs.10/- each for the year 2014-2015. NATCO announces USFDA Filings for Fingolimod, 0.5mg Capsules and Cabazitaxel 60mg/1.5ml Injection
Natco Pharma Ltd has informed BSE regarding a Press Release dated February 10, 2015, titled "NATCO announces USFDA Filings for Fingolimod, 0.5mg Capsules and Cabazitaxel 60mg/1.5ml Injection". Q3 results on Feb 11, 2015
Natco Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 11, 2015, inter alia, to consider the unaudited financial Results for the quarter ended December 31, 2014 (Q3), to consider Interim Dividend, if any, for the financial year 2014-15 and related matters etc.Further, the Trading Window for dealing in the securities of the Company will be closed from January 30, 2015 to February... Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Natco Pharma Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Natco Pharma Ltd has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 Press Release
Natco Pharma Ltd vide its letter dated January 21, 2015 has submitted to BSE a copy of Press Release. Shareholding Pattern For December 31, 2014
Natco Pharma Ltd has informed BSE about the Shareholding Pattern as on December 31, 2014. Natco Pharma Ltd reply to clarification sought by the exchange
The Exchange has sought clarification from Natco Pharma Ltd with respect to the disclosure dated December 5, 2014 submitted by Natco Pharma Ltd which inter-alia states "Allotment of Equity Shares on Preferential Basis other than Cash" Natco Pharma Ltd was requested to submit its clarification to the Exchange with respect to the following in terms of Clause 36 of the Listing Agreement....